- Eli Lilly (NYSE:LLY) and Sanford-Burnham Medical Research Institute will collaborate on discovering and developing immunological therapies for the treatment of autoimmune disease such as lupus, Sjorgren's syndrome and inflammatory bowel disease.
- The research partnership pairs Lilly's biotechnology capabilities and expertise in immunology with Sanford-Burnham's expertise in fundamental cellular pathways regulating the immune system, with a focus on immune checkpoint networks.
- Sanford-Burnham is a nonprofit independent research institute employing more than 1,000 scientists and staff in San Diego, CA and Orlando, FL.
- Financial terms are undisclosed.